| Mitchell S Humphrey, DO | |
|
4950 Buffalo Rd, Erie, PA 16510-2304 | |
| (814) 899-7000 | |
| (814) 899-0334 |
| Full Name | Mitchell S Humphrey |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 4950 Buffalo Rd, Erie, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538168315 | NPI | - | NPPES |
| 01907892 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS012331 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Vincent Hospital | Erie, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Vincent Medical Education And Research Institute Inc | 3870405137 | 258 |
News Archive
Salk Institute researchers have found that an experimental drug candidate aimed at combating Alzheimer's disease has a host of unexpected anti-aging effects in animals.
In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[31-32]: 543-51), Stephanie Holt, a clinical pharmacologist, and coauthors present the PRISCUS List: a list of medications that carry an increased risk of side effects when given to elderly patients.
Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in Orlando, FL (June 25-29, 2010). Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 12 weeks of treatment with ITCA 650 at both the 20 mcg/day and 40 mcg/day doses.
Hormones released after a brain injury contributes to movement problems on the left and right sides of the body, scientists from Uppsala University and elsewhere can now show in a new study in rats.
As a member of the S100 family, S100A2 is considered a candidate tumor-suppressor gene. Recently, p63 gene, a new member of the p53 gene family, has been studied in the fields of tumorigenesis, cell apoptosis and tissue growth. At present, few studies have been carried out on the expression and relationship of S100A2 and p63 in EC.
› Verified 4 days ago
| Entity Name | St Vincent Medical Education And Research Institute Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902881477 PECOS PAC ID: 3870405137 Enrollment ID: O20031104000576 |
News Archive
Salk Institute researchers have found that an experimental drug candidate aimed at combating Alzheimer's disease has a host of unexpected anti-aging effects in animals.
In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[31-32]: 543-51), Stephanie Holt, a clinical pharmacologist, and coauthors present the PRISCUS List: a list of medications that carry an increased risk of side effects when given to elderly patients.
Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in Orlando, FL (June 25-29, 2010). Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 12 weeks of treatment with ITCA 650 at both the 20 mcg/day and 40 mcg/day doses.
Hormones released after a brain injury contributes to movement problems on the left and right sides of the body, scientists from Uppsala University and elsewhere can now show in a new study in rats.
As a member of the S100 family, S100A2 is considered a candidate tumor-suppressor gene. Recently, p63 gene, a new member of the p53 gene family, has been studied in the fields of tumorigenesis, cell apoptosis and tissue growth. At present, few studies have been carried out on the expression and relationship of S100A2 and p63 in EC.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mitchell S Humphrey, DO 4950 Buffalo Rd, Erie, PA 16510-2304 Ph: (814) 899-7000 | Mitchell S Humphrey, DO 4950 Buffalo Rd, Erie, PA 16510-2304 Ph: (814) 899-7000 |
News Archive
Salk Institute researchers have found that an experimental drug candidate aimed at combating Alzheimer's disease has a host of unexpected anti-aging effects in animals.
In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[31-32]: 543-51), Stephanie Holt, a clinical pharmacologist, and coauthors present the PRISCUS List: a list of medications that carry an increased risk of side effects when given to elderly patients.
Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in Orlando, FL (June 25-29, 2010). Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 12 weeks of treatment with ITCA 650 at both the 20 mcg/day and 40 mcg/day doses.
Hormones released after a brain injury contributes to movement problems on the left and right sides of the body, scientists from Uppsala University and elsewhere can now show in a new study in rats.
As a member of the S100 family, S100A2 is considered a candidate tumor-suppressor gene. Recently, p63 gene, a new member of the p53 gene family, has been studied in the fields of tumorigenesis, cell apoptosis and tissue growth. At present, few studies have been carried out on the expression and relationship of S100A2 and p63 in EC.
› Verified 4 days ago
Mrs. Marsha Sigrid Dietrich-mclean, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 201 State St, Erie, PA 16550 Phone: 814-877-4922 Fax: 814-877-3622 | |
Matthew Heitzenrater, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 State St Ste 401, Erie, PA 16507 Phone: 814-877-5333 Fax: 814-877-5329 | |
Dr. Mary Katherine Lasher, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 2501 W 12th St Ste C4, Erie, PA 16505 Phone: 814-461-6626 | |
Matthew Alan Potts, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5515 Peach St, Erie, PA 16509 Phone: 814-864-4031 | |
David Kruszewski, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3125 French St, Erie, PA 16504 Phone: 814-456-2047 | |
Harry Louis Haus, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3823 W 12th St, Erie, PA 16505 Phone: 814-490-3728 | |
Cecilia T. Urquico, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2501 W 12th St, Suite 1, Erie, PA 16505 Phone: 814-806-1144 Fax: 814-833-0659 |